SPOSETTI, CATERINA
SPOSETTI, CATERINA
Universita' degli Studi di MILANO
Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trial
2024 F. Ligorio, R. Lobefaro, G. Fucà, L. Provenzano, L. Zanenga, V. Nasca, C. Sposetti, G. Salvadori, A. Ficchì, A. Franza, A. Martinetti, E. Sottotetti, B. Formisano, C. Depretto, G. Scaperrotta, A. Belfiore, A. Vingiani, C. Ferraris, G. Pruneri, F. de Braud, C. Vernieri
Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments
2023 C. Valenza, D. Trapani, S. Gandini, C. Sposetti, L. Boscolo Bielo, A. Marra, T. Giarratano, D. Favero, L. Cortesi, L. Moscetti, M. Pistelli, R. Berardi, A. Zambelli, M. Lambertini, L. Del Mastro, V. Guarneri, C. Vernieri, G. Curigliano
Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities
2023 E. Zattarin, I. Taglialatela, R. Lobefaro, R. Leporati, G. Fucà, F. Ligorio, C. Sposetti, L. Provenzano, J. Azzollini, A. Vingiani, C. Ferraris, G. Martelli, S. Manoukian, G. Pruneri, F. de Braud, C. Vernieri
Real-world progression-free survival 2 with CDK4/6 inhibitors plus endocrine therapy and subsequent line: Results from the multicenter SISTER study
2023 S. Morganti, S. Gandini, E. Nicolo, E. Zattarin, C. Corti, A. Verrazzo, P.P.M.B. Giachetti, C. Sposetti, M.G. Razeti, B.T. Salimbeni, L. Boldrini, A.C. Schianca, R. Caputo, C. Vernieri, E. Munzone, M. Lambertini, M. De Laurentiis, G. Viale, G. Curigliano, C. Criscitiello
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
2023 E. Zattarin, D. Presti, L. Mariani, C. Sposetti, R. Leporati, A. Menichetti, C. Corti, C. Benvenuti, G. Fucà, R. Lobefaro, F. Ligorio, L. Provenzano, A. Vingiani, M. Del Vecchio, G. Griguolo, M. Sirico, O. Bernocchi, A. Marra, P. Zagami, E. Agostinetto, F. Jacobs, P. Di Mauro, A. Esposito, C.A. Giorgi, L. Lalli, L. Boldrini, P.P.B. Giacchetti, A.C. Schianca, V. Guarneri, R. Pedersini, A. Losurdo, A. Zambelli, D. Generali, C. Criscitiello, G. Curigliano, G. Pruneri, F. de Braud, M.V. Dieci, C. Vernieri
Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study
2022 M. Niger, F. Nichetti, A. Casadei-Gardini, M.D. Rizzato, C. Pircher, M. Bini, A. Franza, M. Rimini, V. Burgio, C. Sposetti, L. Fornaro, I.G. Rapposelli, F.E. D'Amico, G. Aprile, C. Vivaldi, G.L. Frassineti, M. Milione, G. Leoncini, A. Cappetta, E. Vasile, M. Fassan, F. Morano, F. Perrone, E. Tamborini, G. Pruneri, S. Lonardi, V. Mazzaferro, F. Pietrantonio, M. Di Bartolomeo, F. de Braud